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Abstract
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Over the last several decades Quality of Life (QoL) has become increasingly important as an
indicator of treatment outcomes; particularly in schizophrenia spectrum disorders because of its
close association with functional disability. Numerous studies seeking to elucidate the factors that
contribute to QoL in this population have implicated both symptom severity and cognition in
determining QoL but the findings have been mixed. The critical factors that appear to impede the
lack of consensus in the extant literature examining determinants of QoL include the heterogeneity
of the samples and measures examined as well as medication effects across different studies. Thus,
the present study sought to address some of these issues by examining the relationship between
subjective QoL and both symptom severity and cognitive function in a relatively homogeneous
patient sample of patients and a community control sample assessed for dimensional symptom
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severity. Our results suggest that both global cognitive function and psychiatric symptoms have a
significant impact on the subjective QoL of both people with schizophrenia spectrum disorders
and psychiatrically healthy adults. Specifically, we found that a global index of cognition as well
as self-reported avolitional and depressive symptoms were significantly predictive of QoL in both
samples. These findings highlight the importance of addressing cognitive, depressive and
avolitional symptoms in the treatment of patients with schizophrenia spectrum disorders and
suggest that improvements in these domains may have a meaningful impact on their overall QoL.
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1. Introduction
Quality of Life (QoL) is a multidimensional construct encompassing an individual’s
perception of their position in life in relation to their culture, goals, expectations, standards
and concerns (WHOQOL-Group, 1995). Over the last several decades QoL has become
increasingly important as an indicator of treatment outcomes over a wide range of health and
disease states. This interest in QoL as an outcome measure has been particularly pronounced
in schizophrenia spectrum disorders (SZ) because of its close association with functional
disability; a critical problem for patients with these disorders (Lieberman et al., 2008; Malla
and Payne, 2005).

Author Manuscript

To date, numerous studies of people with SZ have implicated general psychopathology such
as anxiety and depressive symptoms (Dickerson et al., 1998; Huppert et al., 2001; Narvaez et
al., 2008; Reine et al., 2003) as well as the more specific domains of positive and negative
symptoms (Fitzgerald et al., 2001; Norman et al., 2000; Savill et al., 2016) in determining
QoL. A recent meta-analysis (Eack and Newhill, 2007) examining the relative contribution
of psychiatric symptoms to QoL found that these symptoms have a significant, but small,
negative relationship with QoL in patients with SZ. However, these authors acknowledged
that their results were limited by the heterogeneity among the samples included noting that
sample characteristics such as treatment setting (inpatient vs. outpatient) and illness stage
(first-episode vs. chronic), which were commonly intermixed in a given sample, had
systematic effects on the observed interaction between QoL and psychiatric symptoms.
Thus, they argued that a more concise understanding of the relationship between QoL and
symptoms would require the study of more homogeneous samples.
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Numerous studies have also implicated cognitive functioning in variation in QoL among
patients with SZ, although these studies have also produced conflicting results. While some
studies have found positive relationships (Savilla et al., 2008; Ritsner 2007; Alptekin et al.,
2005; Herman 2004) others have found negative relationships (Brekke et al 2001; Dickerson
et al., 1998; Narvaez et al 2008) and yet others have found no relationship (Brissos et al
2005; Chino et al 2009; Hofer et al 2005; Smith et al 1999). Similar to the findings
examining the relation between QoL and symptoms, however, data derived from a recent
meta-analysis of the relation between QoL and cognition (Tolman and Kurtz, 2012) also
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suggests that methodological differences are likely hindering consensus about the nature of
the relationship. This meta-analysis indicated that cognition had a moderate effect on
measures of objective QoL, which is typically clinician rated, but no effect on subjective
QoL, which is typically self-reported. However, similar to the prior meta-analysis on the
relation between symptoms and QoL, Tolman and Kurtz (2012) concluded that the
intermixing of samples with different clinical characteristics was likely impacting this latter
finding, which was found to be statistically unstable.

Author Manuscript

One critical issue that was not addressed by either of the aforementioned meta-analyses was
the specific way in which subjective QoL was measured. Although both studies
differentiated between objective and subjective QoL, a critical distinction given that they are
only modestly correlated (Sainfort et al. 1996; Kusel et al. 2007; Bengtsson-Tops et al.
2005), they did not differentiate between general and population-specific measures of
subjective QoL. For example, subjective QoL in patients with SZ is commonly measured
using the Quality of Life Interview (Lehman 1988), which was specifically designed for
people with serious mental illness and thus, assesses what is deemed clinically relevant in
this population and is not typically viewed as valid for measuring QoL in non-psychiatric
populations. More recent studies however, have begun to employ more general scales such
as the World Health Organization Quality of Life Assessment (WHOQOL) that are valid in
both patient and healthy samples. These more general scales appear to be less sensitive to
variations in the characteristics of a specific illness such as SZ (Orsel et al. 2004) and thus,
may reflect a more comprehensive assessment of QoL. In both aforementioned metaanalyses, studies using both population-specific and general measures of QoL were
examined collectively resulting in perhaps an even more turbid understanding of the relation
between clinical factors and subjective QoL.
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Notably, prior work has also found that antipsychotic medications, which have a wide range
of effects on both symptoms and cognitive function as well as a range of adverse effects,
also contribute to variation in QoL in SZ patients. For example, Ritsner et al (2004) found
that in a group of patients whose symptoms were stabilized on an antipsychotic medication,
those patients who were experiencing adverse events reported significantly lower QoL than
those who were not experiencing adverse events. Moreover, a recent randomized controlled
trial found that patients taking second generation antipsychotic medications experienced a
significantly greater improvement in subjective QoL than those taking first generation
agents; an effect that the authors partially attributed to fewer adverse events. Thus, the study
of an unmedicated sample examined in parallel to the medicated patient sample might lead
to a better understanding of how both symptom severity and cognitive function relate to
subjective QoL.

Author Manuscript

In addition to these methodological complications, recent work has stressed the need for a
more dimensional view of the negative symptom construct. Factor analytic studies have
consistently demonstrated that negative symptoms can be separated into two broad
dimensions: a motivational dimension consisting of avolition, anhedonia and asociality and
an expressivity dimension consisting of blunted affect and alogia (Blanchard and Cohen,
2006; Kirkpatrick et al., 2006; Kring et al., 2013). While both of these dimensions may be
critical to functional outcomes, data suggests that deficits in the motivational dimension have
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the greatest effects on functional disability. For example Foussias et al. (2009) found that
motivational deficits accounted for 74% of the variance in functional disability in SZ
patients, with no additional contribution of deficits in expressivity. Notably, the only study to
date that has sought to assess the differential contribution of dimensional measures of
negative symptoms to patients’ subjective QoL found that QoL was exclusively related to
motivational deficits (Savill et al., 2016). Thus, given the relationship between functional
disability and QoL, examination of the role of these two facets of negative symptoms as
determinants of QoL seems timely.

Author Manuscript

The present study aimed to examine the relationship between subjective QoL and both
symptom severity and neurocognitive function in 2 distinct samples that varied across a
spectrum of symptom severity including a general population sample and a patient sample.
Our approach allowed us to address several of the limitations of previous studies. Most
notably, in an effort to address limitations of previous work involving the intermixing of
sample characteristics including early vs. chronic illness and inpatient vs. outpatient
treatment setting, we examined a relatively homogenous group of chronic patients with SZ
being treated in an outpatient setting for at least six months. Given that subjective QoL
represents how a person feels about their “position in life”, we believe that this latter criteria
is critical. Patients who are, or were in the recent past, hospitalized at the time of assessment
not only have limited control over their daily lives, but they are also unlikely to feel positive
about it. Additionally, to address concerns related to the effects of medication status, we
examined these relationships using identical measures in a sample of community controls
who did not have a psychiatric diagnosis and were not taking any psychotropic medication.
Finally, to address the specific effects of different dimensions of negative symptom on QoL,
measures encompassing both the motivational and expressivity dimensions were examined.

Author Manuscript

2. Method
2.1 Participants

Author Manuscript

The sample was comprised of 149 chronic, stable outpatients with schizophrenia or
schizoaffective disorder (95 males, 54 females; MIllness Duration = 14.42 ± 4.86 years) and
408 healthy adult volunteers (133 males, 275 females). Patient participants were recruited
from the Zucker Hillside Hospital (ZHH), a division of Northwell Health, for an NIMHfunded study on functional outcome in schizophrenia (MH079800 to AKM). Patient
participants were excluded from the study if they had a psychiatric hospitalization within the
preceding 6 months, met diagnostic criteria for current substance abuse (within the past
month), or had a history of CNS trauma, neurological disorder or intellectual disability.
Healthy volunteers were recruited from the general population via word of mouth,
newspaper and internet advertisements and posted flyers for an NIMH-funded study of
subclinical psychopathology (MH086756 to PD). Healthy participants were excluded from
the study if they had an Axis I affective or psychotic disorder diagnosis, active or recent
substance abuse (as determined by urine toxicology) or any disorder known to affect the
brain. The patient and control samples used in the present study represent subsets of larger
samples and were selected based on the availability of data from the self-report measures
used in the analyses. The limited availability of the self-report data was due to the late
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addition of these measurements to the assessment schedules of these studies. All participants
provided written informed consent to a protocol approved by the Institutional Review Board
of Northwell Health.
2.2 Clinical Assessments

Author Manuscript

2.2.1 Diagnostic Interviews—Patient participants were administered the Structured
Clinical Interview for the DSM-IV Axis I Disorders, Patient edition(SCID-I/P) (First et al.,
1995b) by Ph.D. or Master’s level psychometricians. Information obtained from the SCID
was supplemented by a review of medical records and interviews with family informants,
whenever possible, and compiled into a narrative case summary. Diagnoses were then
determined by a consensus among a minimum of three senior ZHH faculty, after a thorough
review of the SCID and the corroborating information comprising the narrative case
summary. Healthy participants were initially administered the Structured Clinical Interview
for the DSM-IV, Non-Patient edition (SCID-I/NP) (First et al., 1995a) by Ph.D. or Master’s
level psychometricians. Information obtained from the SCID was compiled into a narrative
case summary and absence of pathology was determined by consensus among two senior
members of the ZHH faculty.

Author Manuscript

2.2.2 Assessment of Psychopathology—All participants were assessed using the
Community Assessment of Psychic Experiences (CAPE) (Stefanis et al., 2002). The CAPE
is a 42-item, self-report questionnaire that measures three dimensions of subclinical
psychopathology including positive, negative and depressive symptoms. The CAPE provides
scores on each of the three dimensions as well as a total score representing the overall
severity of symptoms. The present study sought to assess the differential effects of specific
symptom domains on subjective QoL, with a particular focus on negative symptoms. Thus,
although we utilized the standard positive and depressive subscale scores we used the more
specific negative symptom subscales described by Barragan et al. (2011), which includes
subscale scores for social withdrawal, affective flattening and avolition.

Author Manuscript

Patient participants were also assessed using standard clinician-administered rating scales to
assess symptom severity during the week preceding the interview. These scales included the
Brief Psychiatric Rating Scale (BPRS-Hillside version) (Woerner et al., 1988), the Scale for
the Assessment of Negative Symptoms (SANS-Hillside version) (Robinson et al., 2000) and
the 24-item Hamilton Rating Scale for Depression (HRSD-24) (Hamilton, 1967). These
assessments were completed the same day as the CAPE. All clinician-administered scales
were administered by Ph.D. or Master’s level psychometricians. Inter-rater reliability on all
measures, assessed annually using gold standard videotaped interviews, was high (all
Kappa’s > .80).
2.2.3 Assessment of Quality of Life—To assess subjective QoL, we administered the
Quality of Life Scale (QOLS) (Burckhardt and Anderson, 2003), a 16-item self-report
measure that assesses six conceptual domains of quality of life including: 1) material and
physical well-being, 2) relationships with other people, 3) social, community and civic
activities, 4) personal development, 5) fulfillment and recreation and 6) independence. The
QOLS is a reliable and well-validated instrument for measuring QoL from the perspective of
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patients with chronic illness. Critical to the present study, and in contrast to quality of life
measures typically used in patients with schizophrenia however, it is also well validated in
samples of healthy individuals and has been shown to produce similar scores across different
age, sex and racial groups (Burckhardt and Anderson, 2003). The QOLS is scored by adding
up the score on each item to yield a total score ranging from 16 to 112 with higher scores
indicating a better quality of life.
2.3 Neurocognitive Assessment

Author Manuscript

To assess neurocognitive functioning, The MATRICS Consensus Cognitive Battery (MCCB)
was administered to all participants. The MCCB is comprised of 10 standardized cognitive
measures that capture functioning within seven cognitive domains that are most related to
psychotic disorders (Nuechterlein et al., 2008). Although the MCCB provides scores on a
range of cognitive domains, in the present study we only used the MCCB Composite score,
which provides an index of global cognitive ability.
2.4 Statistical Analysis

Author Manuscript

To examine the contribution of self-rated positive, negative and depressive symptoms to
subjective QoL we carried out two multiple linear regressions; one in patients and one in
healthy volunteers, which both employed the same structure. We utilized a block-wise
approach to determine the amount of variance in subjective QoL that could be accounted for
by global cognitive function and self-reported symptom severity above and beyond the
effects of sex and age. Thus, a three-block model was employed in which the first block
examined only the effects of age and sex on QoL, the second block included the Composite
Score derived from the MCCB and the final block included the overall severity of selfreported symptoms including, positive, depressive, and three domains of negative symptoms
(social withdrawal, flat affect, avolition).

3. Results
3.1 Demographics

Author Manuscript

Comparison of demographic characteristics between patients and healthy volunteers
revealed significant differences in the distributions of males and females as well as the
distribution of racial groups. Specifically, the group of healthy volunteers had a significantly
higher proportion of females and fewer minorities than the patient group. These data are
shown in Table 1. Consistent with our prior results (DeRosse et al., 2014b), scores on the
CAPE were not normally distributed for either patients or healthy volunteers and thus,
comparisons on these measures were carried out using Mann-Whitney U tests. QOLS as
well as MCCB Composite scores were normally distributed in both groups and comparisons
were conducted using t-tests. As expected, patients scored significantly higher on all CAPE
subscales, lower on MCCB Composite score and lower on the QOLS. These results are also
shown in Table 1.
3.2 Healthy Volunteers
In healthy volunteers, the full regression model accounted for 31% of the variance in QOLS
scores (R2=0.31; (F(8, 119)=7.72, p<.001). The final block of the model, which assessed the
Schizophr Res. Author manuscript; available in PMC 2019 May 01.

DeRosse et al.

Page 7

Author Manuscript

effects of self-reported symptoms above and beyond sex, age and MCCB Composite score,
demonstrated a significant increase in the variance previously accounted for by age, sex and
MCCB Composite alone (R2 change =0.34; F(5, 111)=11.78, p<.001). In the final model, the
specific predictors included MCCB Composite score, self-reported positive symptoms, selfreported depressive symptoms, self-reported social withdrawal and self-reported avolitional
symptoms. These results are shown in Table 2.
3.3 Patients

Author Manuscript

Similarly, the full regression model in patients accounted for 27% of the variance in QOLS
scores (R2=0.27; (F(8, 112)=6.47, p<.001) and the final block of the model demonstrated a
significant increase in the variance previously accounted for by age, sex and MCCB
Composite alone (R2 change =0.21; F(5, 112)=6.86, p<.001). The final model in patients
indicated that the specific predictors of QOLS level included MCCB Composite score, selfreported depressive symptoms and self-reported avolitional symptoms. These results are
shown in Table 2. Additionally, Figure 1 illustrates the relationship we observed between
those predictors of QOLS scores that overlapped in both the patient and healthy volunteer
samples.

Author Manuscript

Although we have previously demonstrated that patients self-reported symptoms are
significantly correlated with scores on clinician administered assessments of the same
symptom constructs (DeRosse et al., 2014b), it is not clear if scores derived from clinicianadministered symptom assessments will relate to subjective QoL in the same way as selfreported symptoms. Thus, to address this question, we repeated the primary regression
analysis in patients using the HRSD-24 total score in place of the CAPE depressive
symptom score, the BPRS Psychosis Factor score in place of CAPE positive symptoms and
the Global SANS scores for affective flattening, avolition and anhedonia in place of the
CAPE negative symptom subscales. The results of this analysis were similar to, although not
entirely consistent with, the results using self-reported measures of symptom severity.
Notably, although we found that the final model using clinician-assessed symptoms was also
significant and accounted for 25% of the variance in QOLS scores (R2=0.25; (F(8, 111)=5.63,
p<.001) the specific predictors only included age, MCCB Composite score and HRSD Total
score; clinician-assessed symptoms of avolition in this model were not significantly
predictive of QOLS scores. These results are shown in Table 2.

4. Discussion

Author Manuscript

The results of the present study suggest that both global cognitive function and psychiatric
symptoms have a significant impact on the subjective QoL of both people with
schizophrenia spectrum disorders and psychiatrically healthy adults. Specifically, we found
that a global index of cognition as well as self-reported avolitional and depressive symptoms
were significantly predictive of QoL in both of our samples. These findings are generally
consistent with prior work in patients indicating that depressive symptoms (Dickerson et al.,
1998; Huppert et al., 2001; Narvaez et al., 2008; Reine et al., 2003) and motivational deficits
(Fitzgerald et al., 2001; Norman et al., 2000; Savill et al., 2016) are among the strongest
predictors of subjective QoL. Moreover, the consistency in the pattern of results relating
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depressive and avolitional symptoms to subjective QoL across both groups suggest that these
effects are not attributable to medication effects as none of the community controls in the
present sample were taking psychotropic medications. Finally, at a general level, the similar
pattern observed in both patient and control samples are consistent with the contemporary
view of psychopathology, including psychotic experiences, as dimensional rather than
dichotomous constructs (van Os, 2010).

Author Manuscript

Examined independently, the findings in the control sample suggest that while subclinical
avolitional symptoms are the strongest predictors of QoL, virtually all domains of
subclinical symptoms are predictive of QoL in this population. Although this finding is
consistent with prior work in this population (Cohen & Davis, 2009), it is somewhat
surprising in that it is not consistent with what we observed in the patient sample. However,
it is likely that the discrepant findings are due less to differences in the actual relationships
and more to our statistical power to detect them. Table 2 clearly indicates similar
relationships in both samples and given the 2.5 fold increase in the control sample (N=408)
relative to the patient sample (N=149), this interpretation is likely. Thus, additional work
with larger patient samples is needed.

Author Manuscript

Surprisingly, although we found that global cognitive function was significantly associated
with subjective QoL in both patient and healthy volunteer groups, the direction of this
relationship differed between groups. In healthy volunteers lower global cognitive function,
whereas in patients, higher global cognitive function, predicted a significantly worse
subjective QoL. Given prior work in this area suggesting a positive relationship between
cognitive function and QoL (Alptekin et al., 2005; Ritsner, 2007) as well as the substantial
literature linking better cognition to better longitudinal outcomes (Green et al., 2004) our
finding was unexpected. However, there are several reports in the literature that are directly
consistent with our finding (Hofer et al., 2005; Narvaez et al., 2008) and in retrospect, this
relationship may be somewhat intuitive. Specifically, patients with relatively intact cognitive
functioning may be more likely to feel that they are not reaching their full potential and thus,
assess their QoL as being poorer. This is consistent with work by Bowie and colleagues
(2007) which found that patients with better cognitive abilities tend to overestimate their
level of disability.

Author Manuscript

Finally, we found that in the patient sample, although clinician assessed depressive
symptoms were associated with subjective QoL, consistent with what was found for selfreported depression, clinician assessed avolitional symptoms were not associated with QoL
in the same way as self-reported avolitional symptoms. This finding suggests that clinicians
and patients may differ in how they view avolitional symptoms. It is likely that this
discrepancy, at least in part, is related to the specific scales used in the present study.
However, it may also reflect fundamental differences between the objective narrative
clinicians have, and the subjective narratives that patients have about psychiatric symptoms.
Indeed, although some data suggests that severely ill patients are unable to accurately report
negative symptoms (Hamera et al., 1996; Selten et al., 2000), more recent studies have
suggested that self-report measures may be both valid and useful in this patient population
(Dollfus et al., 2016), especially in the assessment of treatment outcome and overall QoL
(Fleischhacker et al., 2005; Lindstrom et al., 2001; Ohata et al., 2014). Thus, the present
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findings may add to a growing literature emphasizing the utility of self-reported symptoms
in assessing patient-centered outcomes.
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Several limitations of the present study should be noted. First, although the CAPE can be
scored to produce subscale scores that reflect a dimensional assessment of negative
symptoms, it was not specifically designed for this purpose. It should be noted, however, that
the negative symptom subscale scores derived from the CAPE were highly correlated with
their clinician-rated counterparts (all rho’s > .60; all p’s <.01). Nevertheless, future efforts
seeking to examine the effects of different dimensions of negative symptoms on QoL should
utilize more comprehensive measures of these constructs. Additionally, our analyses did not
examine the effects of variation within the different cognitive domains assessed by the
MCCB but rather, only examined the composite score as an index of global cognitive
function. Given our patient sample size, however, the inclusion of all 7 domains captured by
the MCCB in our analyses would have substantially reduced our power to detect any
meaningful effects. Thus, using the composite score represented a compromise that allowed
us to maintain adequate power while still addressing the more global contribution of
cognitive function to QoL.

Author Manuscript

Despite these limitations, the results of the present study have several important
implications. First, they suggest that even at subclinical levels, depressive and avolitional
symptoms have a meaningful impact on the overall subjective QoL of those experiencing
them. Second, these results complement recent work which finds an overlap in the risk
factors associated with the development of both clinically-significant and subclinical
symptoms (Linscott and van Os, 2013) and supports other work suggesting that they may
also have similar consequences (DeRosse et al., 2014a; DeRosse et al., 2014b). These
findings highlight the importance of addressing depressive and avolitional symptoms in the
treatment of patients with schizophrenia spectrum disorders and suggest that improvements
in these symptom domains may have a meaningful impact on their overall QoL. Finally,
these findings collectively highlight the need for the type of approach championed by the
Research Domain Criteria (RDoC) which calls for the recognition that most clinical
problems cut across conventional diagnostic boundaries and exist along a dimension from
healthy to various levels of pathological.
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Figure 1.
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Simple scatterplots illustrating the relationship between: a) global cognitive function as
measured by the MCCB Composite score b) self-reported avolitional symptoms and c) selfreported depressive symptoms (y-axes) and subjective Quality of Life (x-axes) in patients
with schizophrenia or schizoaffective disorder (N=149) and healthy volunteers (N=408).
Abbreviations: QOLS: Quality of Life Scale (Burckhardt & Anderson, 2003); CAPE:
Community Assessment of Psychic Experiences (Stefanis et al., 2002); MCCB: MATRICS

Consensus Cognitive Battery (Neuchterlein et al., 2004)
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Table 1

Author Manuscript

Descriptive statistics and comparisons between the patients and healthy volunteers assessed in the present
study.
Patient (N=149)

Control (N+408)

Statistic

p value

Mean Age (SD)

40.61 (11.65)

39.50 (16.73)

t=0.75

0.45

Percent Female

36.24

67.4

χ2=43.83

<.001

χ2=17.86

Race

White

67

257

Black

61

61

Other

21

55

79.20 (16.82)

92.95 (11.86)

t=9.18

<.001

Positive

32.25 (10.14)

23.35 (3.51)

U=49,956

<.001

Depressive

14.53 (4.26)

11.25 (2.20)

U=45,145

<.001

Social Withrawal

5.15 (1.73)

4.00 (1.23)

U=43,033

<.001

Flat Affect

4.88 (2.01)

3.53 (0.93)

U=43,222

<.001

Avolition

14.47 (4.81)

10.78 (2.56)

U=45,202

<.001

BPRS Psychosis

5.83 (2.85)

n/a

n/a

n/a

HRSD-24

12.8 (7.34)

n/a

n/a

n/a

SANS Global Asociality/Anhedonia

2.17 (1.13)

n/a

n/a

n/a

SANS Global Affective Flattening

1.85 (1.26)

n/a

n/a

n/a

SANS Global Avolition

2.50 (1.12)

n/a

n/a

n/a

Mean QOLS (SD)

Total Score

Author Manuscript

Mean CAPE (SD)

Mean Clinician-based (SD)

Author Manuscript
Author Manuscript
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Table 2

Author Manuscript

Regression results for healthy volunteers (top) and patients (middle) in which models included self-reported
symptoms. The bottom segment of the table presents the regression results for the same set of patients in
which the model replaced self-reported symptoms with clinician assessed symptoms.

Author Manuscript

Final Model

Variable

β

t

p value

Controls

Age

0.002

0.03

0.976

Sex

0.08

0.98

0.33

MCCB Composite

0.12

2.42

0.02

CAPE Positive

0.19

2.02

0.05

CAPE Depressive

−0.26

2.44

0.02

CAPE Social Withdrawal

−0.18

1.99

0.05

CAPE Flattened Affect

0.14

1.46

0.15

CAPE Avolition

−0.42

3.46

0.001

Age

−0.14

1.73

0.09

Sex

0.02

0.28

0.78

MCCB Composite

−0.17

2.02

0.05

CAPE Positive

0.08

0.83

0.41

CAPE Depressive

−3.27

−2.6

0.01

CAPE Social Withdrawal

0.12

1.13

0.26

CAPE Flattened Affect

0.01

0.08

0.94

CAPE Avolition

−0.32

2.1

0.04

Age

−0.18

2.09

0.04

Sex

0.03

0.34

0.74

MCCB Composite

−0.28

3.16

0.002

BPRS Psychosis

0.07

0.8

0.42

HRSD-24

−0.39

4.03

<.001

SANS Global Asociality/Anhedonia

−0.13

1.31

0.19

SANS Global Affective Flattening

−0.05

0.59

0.55

SANS Global Avolition

−0.06

0.61

0.54

Patients Self-Report

Patients Clinician Assessments
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